Clinical Trials

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06397313 2025-09-23

POTAMI-61

Phase 2 Recruiting

230 enrolled

Neoplasm Metastasis, Primary Myelofibrosis

NCT05223920 2025-09-22

MK-3543-005

81 enrolled 13 charts

Phase 1/2 Active not recruiting

Thrombocythemia, Essential, Primary Myelofibrosis

NCT04817007 2025-09-10

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

216 enrolled

Primary Myelofibrosis

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

4 enrolled 10 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT03952039 2025-08-28

FREEDOM2

Phase 3 Completed

202 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06378437 2025-08-19

A Study of GLB-001 in Patients With Myeloid Malignancies

Phase 1 Recruiting

108 enrolled

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3 Recruiting

150 enrolled

Phase 1 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

21 enrolled

Phase 3 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT04717414 2025-07-10

INDEPENDENCE

313 enrolled

Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01688011 2025-07-03

Connect® Myeloid Disease Registry

Terminated

2,013 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Phase 1 Completed

38 enrolled 14 charts

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

90 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04472598 2025-02-21

TRANSFORM-1

Phase 3 Completed

252 enrolled

Phase 1 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

85 enrolled

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT05488548 2025-01-14

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Phase 1 Recruiting

75 enrolled

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT02268253 2025-01-06

Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

Phase 1/2 Completed

82 enrolled 15 charts

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03755518 2024-12-12

FREEDOM

Phase 3 Terminated

38 enrolled 23 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT00522990 2024-08-02

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Phase 1/2 Terminated

48 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT03441113 2024-05-16

Extended Access of Momelotinib in Adults With Myelofibrosis

237 enrolled

Neoplasms, Primary Myelofibrosis

NCT04655118 2024-05-10

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

Phase 2 Recruiting

121 enrolled

Mastocytosis, Systemic, Primary Myelofibrosis

NCT03592576 2024-05-06

Expanded Access to Navitoclax

No longer available

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Terminated

74 enrolled 40 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT04771572 2024-04-24

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Phase 1 Recruiting

100 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05444972 2023-12-11

METER

Completed

998 enrolled

Neoplasms, Primary Myelofibrosis

NCT04480086 2023-08-29

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase 1 Terminated

1 enrolled

Neoplasms, Primary Myelofibrosis

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Classical hematologyMyeloid

95 enrolled 32 charts

Anemia, Primary Myelofibrosis

NCT04896112 2023-06-18

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Phase 1 Withdrawn

Polycythemia Vera, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT02440685 2023-06-07

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Phase 1/2 Terminated

51 enrolled 18 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT03886831 2023-03-28

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Phase 1 Completed

232 enrolled

Anemia, Refractory, with Excess of Blasts, Carcinoma, Adenoid Cystic, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT04866056 2022-12-01

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Phase 1/2 Terminated

1 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Phase 1/2 Withdrawn

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT03144687 2022-06-16

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

23 enrolled 31 charts

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02953704 2022-05-13

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Completed

1,469 enrolled

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04709458 2022-05-03

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Phase 1 Unknown

10 enrolled